Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | PNP | P00491 | 2/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 2/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5203956 | 1.00 | PDE4D (0.53) | PDE4DPDE3ASLC29A1ADORA3HPGD | |
| Phosphoric Acid SCHEMBL21465104 | 0.96 | NT5E (0.51) | PDE4DPDE3ASLC29A1ADORA3HPGD | |
| SCHEMBL546453 | 0.91 | ADORA3 (0.51) | PDE3AADORA3HPGDHINT1NT5E | |
| SCHEMBL4844756 | 0.91 | ADORA3 (0.51) | PDE3AADORA3HPGDHINT1NT5E | |
| SCHEMBL25380147 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL19813683 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL20991026 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL471141 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL13929032 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A | |
| SCHEMBL465582 | 0.90 | ADORA2A (0.51) | ADORA3HPGDHINT1NT5EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 677 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260073515-A1 | METHOD AND SYSTEM FOR AUTOMATED PARAMETRIC MAPPING OF BRAIN METABOLISM | UNIV OF VIRGINIA LICENSING & VENTURES GROUP (US) | 2026-03-12 | — | — | US | claimed |
| EP-4200521-B1 | CONVERSION METHOD OF LNG CARRIER STEAM OR HYBRID PROPULSION INSTALLATIONS | GAS SHIPPING ADVISORS S L (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250275730-A1 | AUTOMATION OF THE BLOOD INPUT FUNCTION COMPUTATION PIPELINE FOR DYNAMIC FDG PET FOR HUMAN BRAIN USING MACHINE LEARNING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-09-04 | — | — | US | claimed |
| CN-118339366-A | Conversion method of LNG transport ship steam or hybrid propulsion equipment | 天然气运输咨询公司 | 2024-07-12 | — | — | CN | claimed |
| CN-117901901-A | Remote driving control method, system and medium based on multiple safety mechanisms | 东风悦享科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| WO-2023196474-A1 | AUTOMATION OF THE BLOOD INPUT FUNCTION COMPUTATION PIPELINE FOR DYNAMIC FDG PET FOR HUMAN BRAIN USING MACHINE LEARNING | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4200521-A1 | CONVERSION METHOD OF LNG CARRIER STEAM OR HYBRID PROPULSION INSTALLATIONS | Gas Shipping Advisors, S.L. (ES) | 2023-06-28 | — | — | EP | claimed |
| WO-2023066462-A1 | CONVERSION METHOD OF LNG CARRIER STEAM OR HYBRID PROPULSION INSTALLATIONS | GAS SHIPPING ADVISORS, S.L. (ES) | 2023-04-27 | — | — | WO | claimed |
| CN-115789512-A | Multiple heating system of FSRU regasification device | 上海中远船务工程有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| EP-1819718-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | Sicor Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | SICOR, INC. | 2006-08-03 | — | — | US | claimed |
| WO-2006063105-A1 | DIFLUORONUCLEOSIDES AND PROCESS FOR PREPARATION THEREOF | SICOR INC. (US) | 2006-06-15 | — | — | WO | claimed |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | QLT USA, INC. | 2006-06-08 | — | — | US | claimed |
| US-20040072168-A1 | Novel deoxynucleoside kinase enzyme variants | KNECHT WOLFGANG (SE) | 2004-04-15 | — | — | US | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20040072168-A1 | Novel deoxynucleoside kinase enzyme variants | KNECHT WOLFGANG (SE) | 2004-04-15 | — | — | US | disclosed |
| US-6582947-B1 | Nucleotide sequences coding enzymatic polypeptide for use in the virus treatment of cancer and viral infection | BIO VICI (CH) | 2003-06-24 | — | — | US | disclosed |
| EP-1035202-A2 | A cloning method for DNA fragments using arbitrarily primed PCR | JCR PHARMACEUTICALS CO., LTD. (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173174-A1 | Difluoronucleosides and process for preparation thereof | DUT, NUDT1, DPYD | PDE4D 1971/4885PDE3A 3246/4885SLC29A1 57/4885 |
| US-20060121085-A1 | Formulations for cell-schedule dependent anticancer agents | CDC25A, CCNB1, CCNE1 | PDE4D 4570/4885PDE3A 3393/4885SLC29A1 256/4885 |
| US-20260073515-A1 | METHOD AND SYSTEM FOR AUTOMATED PARAMETRIC MAPPING OF BRAIN METABOLISM | MPI, MVD, CHAT | PDE4D 499/4885PDE3A 1358/4885SLC29A1 667/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | PDE4D 600/4885PDE3A 779/4885SLC29A1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.